Retatrutide 30mg

About Retatrutide

What is Retatrutide?

Retatrutide (CAS 2381089-83-2; also LY3437943) is a synthetic 39-amino-acid peptide designed as a triple agonist of three metabolic receptors: GIP, GLP-1, and glucagon (GCG). A C20 fatty diacid on the backbone extends plasma half-life, which is why research papers often discuss weekly dosing schedules.

Werhner Lab supplies retatrutide as lyophilised powder in 15 mg and 30 mg vials.

CAS: 2381089-83-2. Alternate ID: LY3437943. Molecular weight: ~4731 g/mol. Receptor profile: GIP-R, GLP-1R, and GCG-R at the same time.

How Retatrutide is studied in the literature

The literature focuses on triple-receptor pharmacology and preclinical metabolic models. The following is scientific background only. It does not claim what Werhner Lab material will do in any person.

Body composition and energy-expenditure research

In metabolic models, retatrutide is studied for effects on body composition, adiposity, and energy-expenditure pathways. The question is how simultaneous GIP-R, GLP-1R, and GCG-R activation compares with single- and dual-receptor agonists.

Glucose-regulation pathways

It is also studied in glucose-regulation and incretin-signalling models, including dose-dependent activity at all three target receptors.

Within the incretin class — how Retatrutide differs

Feature	Semaglutide	Tirzepatide	Retatrutide
Receptor activation	GLP-1R only	GIP-R + GLP-1R	GIP-R + GLP-1R + GCG-R
Amino acids	31	39	39
Distinct mechanism	Fatty-acid extension on GLP-1R	Dual incretin	Glucagon arm adds hepatic glucose output and energy-expenditure signals

The glucagon-receptor arm is the distinguishing feature. Neither semaglutide nor tirzepatide activates GCG-R. In research that matters because glucagon agonism is linked to hepatic glucose production and thermogenesis — an energy-expenditure component that single- and dual-agonists lack.

Research areas

• Comparative in-vitro binding and signalling at GIP, GLP-1, and glucagon receptors
• Preclinical metabolic models of body composition and energy expenditure
• Comparison with single- and dual-agonist compounds (semaglutide, tirzepatide)
• Lipid metabolism and hepatic glucose-output pathways (glucagon arm)
• Formulation and stability of long-acting peptide analogues

Specifications

CAS	2381089-83-2
Alternate ID	LY3437943
Molecular weight	~4731 g/mol
Receptor profile	Triple agonist: GIP-R / GLP-1R / GCG-R
Purity	≥ 97.5% (supplier batch spec; CoA per lot)
Form	Lyophilised powder in a sealed glass vial
Sizes	15 mg, 30 mg

Storage

Lyophilised powder: −20°C long term. 2–8°C short term before reconstitution.

Reconstituted: 2–8°C; use within your lab window. Do not freeze after reconstitution unless the protocol requires it.

Quality

• Each batch ships to a stated purity specification
• Lot CoA documents identity and purity
• Use batch numbers RT15-7741 / RT30-5268 when requesting files

Important notice — Research Use Only

Retatrutide is supplied by Werhner Lab strictly as a laboratory research compound. Literature context is background only, not a medical claim, and does not describe effects in any individual. Not a medicine, supplement, or cosmetic. Not offered for human or veterinary use. Not intended to diagnose, treat, cure, or prevent any disease. Laboratory research only. Not for human consumption.